Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
A plain-language summary of the cited sources below. Informational only — not medical advice.
Carbamazepine works by calming overactive nerve cells in the brain. It blocks sodium channels on nerve membranes, which stops nerve cells from firing repeatedly when they become too excited. This action helps control seizures, stabilise mood swings, and reduce certain types of nerve pain. After you take a dose, the medication goes through the liver to be broken down, and the liver produces an active substance that also contributes to the effect. When someone takes carbamazepine regularly, their liver adapts and starts breaking it down faster, which is why the time it stays in the body shortens from around 36 hours after a first dose to between 16 and 24 hours with ongoing use.
Doctors prescribe carbamazepine for several conditions. It is used to control different types of seizures, including partial seizures and generalised tonic-clonic seizures. It is also prescribed for trigeminal neuralgia and glossopharyngeal neuralgia, both of which cause severe facial or throat pain. In addition, carbamazepine is used to treat acute episodes of mania and as a long-term treatment to help prevent mood episodes in people with bipolar affective disorder.
The most common side effects your family member might notice are dizziness, headache, unsteadiness when walking, drowsiness, and fatigue. These effects are often more noticeable when treatment starts or when the dose is increased, and they may lessen over time as the body adjusts.
There are some serious but less common risks you should be aware of. Carbamazepine can, in rare cases, cause dangerous blood disorders where the bone marrow stops producing enough blood cells, and these have sometimes been fatal. It can also cause severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and a condition called DRESS, which involves rash, fever, and effects on internal organs. If your family member develops a rash, high fever, unusual bruising or bleeding, severe fatigue, mouth sores, or yellowing of the skin or eyes, seek medical attention immediately.
Carbamazepine interacts with many other medications because it speeds up the way the liver breaks down other drugs. This means it can reduce the effectiveness of other medicines your family member is taking. The prescribing doctor needs to know about all medications, including over-the-counter products and supplements, to assess whether carbamazepine is safe and whether dose adjustments are needed for other treatments.
Common off-label uses observed in AU practice — none of these are TGA-approved indications for this substance. If the documented purpose is one of these, the prescription falls outside the TGA-approved set and may sit inside the chemical-restraint frame depending on jurisdiction and context.
These are practitioner observations, not TGA-approved indications. A use being off-label does not by itself imply a regulated restrictive practice; review the documented purpose against the observed function in context.
Tier 4 · ObservationThe condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. Clinical criteria: Treatment criteria: Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
“Carbamazepine stabilises hyperexcited nerve membranes, inhibits repetitive neuronal discharges and reduces synaptic propagation of excitatory impulses. It is conceivable that prevention of repetitive firing of sodium-dependent action potentials in depolarised neurons via use- and voltage- dependent blockade of sodium channels may be its main mechanism of action.”
“The elimination half-life of unchanged carbamazepine following a single oral dose averaged 36 hours whereas, after repeated administration which leads to hepatic enzyme induction, it averaged 16 to 24 hours, depending on the duration of treatment. In patients receiving concomitant treatment with other liver-enzyme inducing drugs (e.g. phenytoin, phenobarbitone), half-life values averaging 9 to 10 hours have been found.”
A plain-language summary of the cited sources below. Informational only — not medical advice.
Carbamazepine is a sodium channel blocker within the carboxamide derivatives class, Schedule 4. It binds preferentially to voltage-gated sodium channels in their inactive conformation, preventing repetitive and sustained firing of action potentials; it also has effects on serotonin systems (acting as a serotonin releasing agent and possibly a reuptake inhibitor) and may block voltage-gated calcium channels, reducing neurotransmitter release. TGA-approved indications include complex or simple partial seizures (with or without secondary generalisation), generalised tonic-clonic seizures, mixed seizure patterns, idiopathic trigeminal neuralgia and trigeminal neuralgia due to multiple sclerosis, idiopathic glossopharyngeal neuralgia, treatment of mania, and maintenance treatment of bipolar affective disorders.
The elimination half-life after a single oral dose averages 36 hours; with repeated administration hepatic enzyme induction reduces this to 16–24 hours, and concomitant use of other enzyme-inducing drugs (phenytoin, phenobarbitone) can shorten it further to 9–10 hours. Carbamazepine is metabolised primarily via CYP3A4, which catalyses formation of the active metabolite carbamazepine-10,11-epoxide, and is itself a potent inducer of CYP3A4 and other phase I and phase II hepatic enzymes, reducing plasma concentrations of co-medications metabolised via CYP3A4. Common adverse effects include dizziness, headache, ataxia, drowsiness, and fatigue. Contraindications include known hypersensitivity to carbamazepine or structurally related drugs (including tricyclic antidepressants), atrioventricular block, systemic lupus erythematosus, history of hepatic porphyrias, history of bone marrow depression, concomitant use with monoamine-oxidase inhibitors, hepatic failure, and neonates below 4 weeks of age. Serious adverse effects reported include agranulocytosis, aplastic anaemia, Stevens-Johnson syndrome, toxic epidermal necrolysis, and Drug Rash with Eosinophilia and Systemic Symptoms.
Working under the parallel aged-care framework? Aged-care equivalent →
For prescribing by certain health practitioners Clinical criteria: Treatment criteria: Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“Cytochrome P450 3A4 (CYP 3A4) is the main enzyme catalysing the formation of the active metabolite carbamazepine-10,11-epoxide. Carbamazepine is a potent inducer of CYP3A4 and other phase I and phase II enzyme systems in the liver, and may therefore reduce plasma concentrations of co-medications mainly metabolized by CYP3A4 by induction of their metabolism (see section 4.4 "SPECIAL WARNINGS AND PRECAUTIONS FOR USE").”